SK284143B6 - Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje - Google Patents

Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje Download PDF

Info

Publication number
SK284143B6
SK284143B6 SK1218-97A SK121897A SK284143B6 SK 284143 B6 SK284143 B6 SK 284143B6 SK 121897 A SK121897 A SK 121897A SK 284143 B6 SK284143 B6 SK 284143B6
Authority
SK
Slovakia
Prior art keywords
methyl
thieno
benzodiazepine
piperazinyl
crystalline form
Prior art date
Application number
SK1218-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK121897A3 (en
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel D. Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284143(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of SK121897A3 publication Critical patent/SK121897A3/sk
Publication of SK284143B6 publication Critical patent/SK284143B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
SK1218-97A 1995-03-24 1996-03-22 Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje SK284143B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
SK121897A3 SK121897A3 (en) 1998-03-04
SK284143B6 true SK284143B6 (sk) 2004-10-05

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1218-97A SK284143B6 (sk) 1995-03-24 1996-03-22 Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje

Country Status (48)

Country Link
US (1) US5736541A (da)
EP (3) EP0733635B1 (da)
JP (1) JPH11502535A (da)
KR (1) KR100399688B1 (da)
CN (1) CN1065536C (da)
AP (1) AP828A (da)
AR (2) AR002719A1 (da)
AT (4) ATE204280T1 (da)
AU (1) AU706471B2 (da)
BG (1) BG62619B1 (da)
BR (1) BR9607790A (da)
CA (1) CA2214005C (da)
CH (1) CH690579A5 (da)
CO (1) CO4650278A1 (da)
CZ (1) CZ292688B6 (da)
DE (4) DE19681286T1 (da)
DK (4) DK1445259T3 (da)
EA (1) EA000149B1 (da)
EE (1) EE03489B1 (da)
EG (1) EG23659A (da)
ES (3) ES2159346T3 (da)
FI (1) FI973750L (da)
GB (1) GB2313835B (da)
HU (1) HU224989B1 (da)
IL (1) IL117610A (da)
IS (1) IS1896B (da)
LT (1) LT4349B (da)
LU (1) LU90096B1 (da)
LV (1) LV12018B (da)
MY (1) MY114701A (da)
NO (1) NO314663B1 (da)
NZ (1) NZ306110A (da)
OA (1) OA10510A (da)
PA (1) PA8353701A1 (da)
PE (1) PE44897A1 (da)
PL (1) PL183723B1 (da)
PT (3) PT1445259E (da)
RO (1) RO118872B1 (da)
SE (1) SE9703205D0 (da)
SI (4) SI1095941T1 (da)
SK (1) SK284143B6 (da)
SV (1) SV1996000031A (da)
TR (1) TR199701017T1 (da)
TW (2) TW442488B (da)
UA (1) UA44765C2 (da)
WO (1) WO1996030375A1 (da)
YU (1) YU49478B (da)
ZA (2) ZA962344B (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JPH11512705A (ja) * 1995-09-29 1999-11-02 イーライ・リリー・アンド・カンパニー チック症を処置する方法
TR199801800T2 (xx) * 1996-03-11 1998-12-21 Eli Lilly And Company Uykusuzluk tedavisi.
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
BR9708246A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Metodo para tratamento de dor
CZ298398A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
CA2250155A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
JP2001500878A (ja) * 1996-09-23 2001-01-23 イーライ・リリー・アンド・カンパニー オランザピン二水和物ｄ
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
HK1041199B (en) * 1998-09-30 2005-03-18 Eli Lilly & Company 2-Methyl-thiophenone-benzodiazine formula
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
DE60019461T2 (de) * 1999-12-28 2005-09-22 Cipla Ltd., Bombay Neue polymorphe formen von olanzapin
SK2502003A3 (en) * 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
CA2551806A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries, Ltd. Methods of preparing olanzapine
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
KR20070113277A (ko) * 2005-03-21 2007-11-28 닥터 레디스 레보러터리즈 리미티드 올란자핀의 결정 형태 ｉ의 제조방법
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HUE065427T2 (hu) 2010-08-23 2024-05-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által indukált súlygyarapodás kezelésére
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2014031656A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine haptens and use thereof
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
AU2023208281A1 (en) 2022-01-20 2024-08-01 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof
JP2026501805A (ja) 2023-01-10 2026-01-16 メドインセルル エス．エー． オランザピン組成物及び使用の方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
PT582368E (pt) * 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
YU49478B (sh) 2006-05-25
SI9620040A (sl) 1998-06-30
BG101900A (en) 1999-03-31
IL117610A0 (en) 1996-07-23
DE69630324D1 (de) 2003-11-13
EG23659A (en) 2007-03-26
PT733635E (pt) 2001-12-28
SI1445259T1 (sl) 2006-10-31
AU706471B2 (en) 1999-06-17
PL183723B1 (pl) 2002-07-31
CN1065536C (zh) 2001-05-09
DE69636313T2 (de) 2007-05-31
KR100399688B1 (ko) 2004-02-18
BG62619B1 (bg) 2000-03-31
ZA962342B (en) 1997-09-22
CZ292688B6 (cs) 2003-11-12
DE69614426D1 (de) 2001-09-20
DE69630324T2 (de) 2004-07-29
GB9719819D0 (en) 1997-11-19
LV12018A (lv) 1998-04-20
CO4650278A1 (es) 1998-09-03
GB2313835A (en) 1997-12-10
HUP9802824A3 (en) 2000-01-28
AU5427996A (en) 1996-10-16
AT406771B (de) 2000-08-25
EP0733635A1 (en) 1996-09-25
CN1179160A (zh) 1998-04-15
MX9707183A (es) 1997-11-29
SK121897A3 (en) 1998-03-04
US5736541A (en) 1998-04-07
SI0733635T1 (en) 2002-06-30
DE19681286T1 (de) 1998-04-02
WO1996030375A1 (en) 1996-10-03
DK1095941T3 (da) 2004-02-16
CA2214005C (en) 2001-07-03
LT4349B (lt) 1998-05-25
CZ300097A3 (en) 1997-12-17
BR9607790A (pt) 1998-07-07
MY114701A (en) 2002-12-31
ES2159346T3 (es) 2001-10-01
EP1445259B1 (en) 2006-06-28
ZA962344B (en) 1997-09-22
NZ306110A (en) 1998-09-24
DK1445259T3 (da) 2006-10-16
OA10510A (en) 2002-04-24
EP1095941B1 (en) 2003-10-08
JPH11502535A (ja) 1999-03-02
AR002719A1 (es) 1998-04-29
SV1996000031A (es) 1998-03-27
TW442488B (en) 2001-06-23
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
LU90096B1 (fr) 1997-07-22
FI973750A0 (fi) 1997-09-22
IL117610A (en) 2001-08-26
DK0733635T3 (da) 2001-10-08
NO974365D0 (no) 1997-09-22
ATE331719T1 (de) 2006-07-15
EA000149B1 (ru) 1998-10-29
PT1095941E (pt) 2004-02-27
KR19980703188A (ko) 1998-10-15
HK1013988A1 (en) 1999-09-17
EA199700262A1 (ru) 1998-02-26
ATE204280T1 (de) 2001-09-15
ES2266719T3 (es) 2007-03-01
HUP9802824A2 (hu) 1999-06-28
PL322501A1 (en) 1998-02-02
ATE251627T1 (de) 2003-10-15
FI973750A7 (fi) 1997-09-22
GB2313835B (en) 1998-09-16
DE69614426T2 (de) 2002-05-23
NO974365L (no) 1997-09-22
YU17796A (sh) 1999-03-04
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
ATA902196A (de) 2000-01-15
TW513432B (en) 2002-12-11
UA44765C2 (uk) 2002-03-15
IS4564A (is) 1997-09-22
SE9703205L (sv) 1997-09-05
NO314663B1 (no) 2003-04-28
EP1095941A1 (en) 2001-05-02
DE69636313D1 (de) 2006-08-10
RO118872B1 (ro) 2003-12-30
AP828A (en) 2000-04-28
FI973750L (fi) 1997-09-22
CA2214005A1 (en) 1996-10-03
EP1445259A1 (en) 2004-08-11
DK108997A (da) 1997-11-12
IS1896B (is) 2003-10-20
EE9700232A (et) 1998-04-15
SI9620040B (sl) 2002-02-28
SI1095941T1 (en) 2003-12-31
HU224989B1 (en) 2006-05-29
ES2208220T3 (es) 2004-06-16
PE44897A1 (es) 1997-10-22
TR199701017T1 (xx) 1998-01-21
CH690579A5 (de) 2000-10-31
LT97148A (lt) 1998-01-26
LV12018B (en) 1998-09-20
EE03489B1 (et) 2001-08-15
EP0733635B1 (en) 2001-08-16
SE9703205D0 (sv) 1997-09-05

Similar Documents

Publication Publication Date Title
SK284143B6 (sk) Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje
SK128297A3 (en) Oral 2-methyl-thieno-benzodiazepine formulation and method of preparing the same
PL196068B1 (pl) Związek będący krystalicznym polimorfem, Dihydratem E olanzapiny i sposób wytwarzania zasadniczo czystej postaci II olanzapiny
KR19990087715A (ko) 자폐증의 치료 방법
WO1996038151A1 (en) Method for treating cognitive dysfunction
HK1013988B (en) Crystal forms of a thieno(2,3-b)(1,5) benzodiazepine derivative and process for their preparation
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
IL126157A (en) Medicinal products containing olenzapine for the treatment of hyper-aggression
US20020177590A1 (en) Method for treating cognitive dysfunction
MXPA98007430A (en) Medications for the treatment of the car

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140322